Journal of controlled release : official journal of the Controlled Release Society2026ReviewNon-viral Gene DeliveryDrug Delivery
Jiang Y, Sun R, Zhang J, Wang C, Chen X, Wu D
Cancer remains a leading cause of mortality worldwide. Conventional modalities, namely surgery, radiotherapy, chemotherapy, and immunotherapy, continue to face substantial limitations. The advent of gene therapy, particularly CRISPR-based genome editing, offers new opportunities to overcome these barriers.
Read the article →The Journal of pharmacy and pharmacology2026ReviewDrug Delivery
Chauhan A, Kumar M, Awasthi A
To provide a comprehensive overview of lipid-based nanocarriers for oxaliplatin (OXA) delivery in colorectal cancer (CRC), with emphasis on their potential to improve pharmacokinetics, enhance tumour accumulation, enable controlled drug release, and overcome OXA resistance. Relevant literature on OXA, CRC…
Read the article →International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery
Tabibzadeh S, Meng F, Asghariazar V, Safarzadeh E, Esmaeili A, Ten Hagen Tlm, Et Al.
Cancer vaccines have emerged as a promising immunotherapeutic strategy for inducing durable and tumour-specific immune responses; however, their clinical efficacy remains limited by poor antigen immunogenicity, inefficient delivery, tumor heterogeneity, and the highly immunosuppressive tumor microenvironment (TME).
Read the article →Frontiers in pharmacology2026ReviewDrug Delivery
Ding L, Staskiewicz A, Kao J, Wang X
Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)…
Read the article →Expert opinion on drug delivery2026ReviewNon-viral Gene Delivery
Mohammad Gholinia Sarpoli L, Hamblin Mr, Ebrahimifard M
Non-viral gene delivery systems offer adaptable alternatives to viral vectors for gene therapy. Nevertheless, their clinical translation remains limited by biological barriers and the pathological tissue microenvironment. Tumors exhibit alterations in the tissue microenvironment, including extracellular acidosis…
Read the article →Frontiers in immunology2026ReviewDrug Delivery
Liu J, Yang Y, Zhang W, Liu J, Yu Y, Song Y, Et Al.
Natural killer (NK) cells are essential components of innate immunity and play a pivotal role in tumor surveillance through direct cytotoxicity and immune regulation. In recent years, NK-cell-derived extracellular vesicles (NK-EVs) have emerged as a promising cell-free therapeutic modality that preserves key…
Read the article →International journal of molecular sciences2026ReviewNon-viral Gene DeliveryDrug Delivery
Rachamala Hk, Angom Rs, Marepally S
In recent years, lipid nanoparticles (LNPs) have shown great promise as highly flexible delivery systems for cancer vaccines, which enable effective cargo delivery and allow for controlling their distribution, cell-targeting ability and immunogenicity. Innovations in ionizable lipid chemistry, biodegradable…
Read the article →Frontiers in oncology2026ReviewDrug Delivery
Beaugé L, Ibarra Le
Photo-assisted therapies have emerged as promising strategies for cancer treatment by combining localized tumor ablation with the induction of systemic antitumor immune responses. Despite encouraging preclinical and clinical advances, their therapeutic efficacy remains limited by the unfavorable pharmacokinetics…
Read the article →International journal of nanomedicine2026ReviewDrug Delivery
Li X, Yu Y, Xie Y, He P, Chen Y, Guo Z, Et Al.
Macrophages are highly plastic immune cells with tumor-homing capacity and immunomodulatory functions, making macrophage-based nanoplatforms attractive for cancer immunotherapy. Macrophage-based nanoplatforms include macrophage-derived extracellular vesicles (EVs), macrophage membrane-coated nanoparticles, and live…
Read the article →